We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
REVIEW
[Novel targeted therapy in multiple myeloma].
Recently, new agents have explored in the treatment of multiple myeloma (MM), according to the identification of the novel pathogenetic mechanisms. Proteasome inhibitor (bortezomib) and immunomodulatory drugs (thalidomide and lenalidomide) now play important roles in the treatment of MM, and they have resulted in an improvement of the outcome of the patients. However, MM remains incurable and the prognosis is very poor in the patients who become refractory to bortezomib and IMiDs. New agents with novel mechanism of action in MM (monoclonal antibodies, deacetylase inhibitors, and so on) will be discussed in this review.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app